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The GABAB receptor agonist, baclofen, is used to treat muscle tightness and cramping
caused by spasticity in a number of disorders including multiple sclerosis (MS), but
its precise mechanism of action is unknown. Neuroinflammation drives the central
pathology in MS and is mediated by both immunoreactive glial cells and invading
lymphocytes. Furthermore, a body of data indicates that the Toll-like receptor (TLR)
family of innate immune receptors is implicated in MS progression. In the present
study we investigated whether modulation of GABAB receptors using baclofen can
exert anti-inflammatory effects by targeting TLR3 and(or) TLR4-induced inflammatory
signaling in murine glial cells and human peripheral blood mononuclear cells (PBMCs)
isolated from healthy control individuals and patients with the relapse-remitting (RR)
form of MS. TLR3 and TLR4 stimulation promoted the nuclear sequestration of NF-
κB and pro-inflammatory cytokine expression in murine glia, while TLR4, but not
TLR3, promoted pro-inflammatory cytokine expression in PBMCs isolated from both
healthy donors and RR-MS patients. Importantly, this effect was exacerbated in RR-
MS patient immune cells. We present further evidence that baclofen dose-dependently
attenuated TLR3- and TLR4-induced inflammatory signaling in primary glial cells. Pre-
exposure of PBMCs isolated from healthy donors to baclofen attenuated TLR4-induced
TNF-α expression, but did not affect TLR4-induced TNF-α expression in RR-MS patient
PBMCs. Interestingly, mRNA expression of the GABAB receptor was reduced in PBMCs
from RR-MS donors when compared to healthy controls, an effect that might contribute
to the differential sensitivity to baclofen seen in healthy and RR-MS patient cells. Overall
these findings indicate that baclofen differentially regulates TLR3 and TLR4 signaling
in glia and immune cells, and offers insight on the role of baclofen in the treatment of
neuroinflammatory disease states including MS.
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Introduction
Autoimmunity drives the development of multiple sclerosis
(MS), involving central nervous system (CNS) inﬁltration of
immune cells, myelin degradation, reactive changes in glia and
axonal loss (Compston and Coles, 2002). The innate immune
system has received much interest as having a deﬁned role
in the progression and/or etiology of MS (O’Brien et al.,
2008; Downer, 2011). Innate immunity is regulated by complex
mechanisms involving pattern-recognition receptors (PRRs)
that recognize molecular signatures of microbes. Intracellular
signaling triggered by PRRs leads to transcriptional expression
of inﬂammatory mediators that coordinate the elimination
of pathogens (Akira et al., 2006). If left unchecked, or
not tightly regulated, dysregulation of this system can lead
to conditions such as sepsis and autoimmunity (Lehnardt,
2010).
Toll-like receptors (TLRs) belong to the family of signaling
PRRs (Jeannin et al., 2008) that initiate innate immune
reactions by activating transcription factors such as nuclear factor
(NF)-κB, in addition to inducing the expression of interferons
(IFNs) and cytokines. Thus far, 12 functional TLRs have been
identiﬁed in mice, and 10 in humans (O’Neill, 2004; Kawai and
Akira, 2006). TLRs are localized in endosomal compartments
(including TLR3, TLR7, TLR8, TLR9), or are cell membrane-
bound (as with all other TLRs; O’Neill, 2004), and couple
to speciﬁc signaling cascades, inducing gene transcription and
controlling immune processes, with this speciﬁcity reliant on
the TLR adaptor proteins recruited (O’Neill, 2004). All TLRs
(with the exception of TLR3), recruit the adaptor myeloid
diﬀerentiation factor 88 (MyD88; Medzhitov et al., 1998).
TLR3 (and TLR4) induces MyD88-independent signaling to
couple to NF-κB via Toll-Interleukin-1 Receptor (TIR)-domain-
containing adaptor-inducing IFN-β (TRIF) protein. TLRs are
key players in CNS diseases, and with respect to MS, key roles
of TLRs have been shown in murine models of MS (Touil
et al., 2006), while the expression of TLRs characterized on
immune cells and CNS glia and neurons (Nishimura and Naito,
2005).
Gamma amino butyric acid (GABA) is the major inhibitory
amino acid neurotransmitter in the brain (Cobb et al., 1995).
GABA exerts its eﬀects through the ionotropic receptors,
GABAA/GABAA−ρ and the metabotropic receptor GABAB
(Bormann, 2000; Campagna-Slater and Weaver, 2007; Pinard
et al., 2010), and GABA receptor transcripts are present in
neurons, glia (Lee et al., 2011; Vélez-Fort et al., 2012), and
immune cells (Bhat et al., 2010). There is a growing body
of evidence pointing to the key role of GABA receptors
in neuroinﬂammation (Ziegler et al., 1980; Tyagi et al.,
2015), and recent reports has identiﬁed that modulation of
the GABAergic system occurs in MS (Han et al., 2008;
Carmans et al., 2013). Indeed, GABA insuﬃciency has been
identiﬁed in MS patients (Demakova et al., 2003), while
intrathecal administration of the GABAB receptor agonist,
baclofen, is used as a treatment strategy to control spasticity
in patients with MS (Gunnarsson and Samuelsson, 2015).
Furthermore, enhancing endogenous GABA via administration
of the GABA-degrading enzyme GABA-transaminase (GABA-
T), has been shown to be protective in an experimental
autoimmune encephalomyelitis (EAE) mouse model (Carmans
et al., 2013), indicating that increasing endogenous GABA also
has therapeutic potential in the murine model of MS. In support
of these in vivo ﬁndings, in vitro studies have shown that
baclofen reduces TLR4-induced release of pro-inﬂammatory
cytokines from primary murine microglia (Kuhn et al., 2004),
indicating that cross talk may exist between the GABAergic
and TLR systems, with relevance to inﬂammatory signaling
events.
GABAB receptors are metabotropic Gi/Go-coupled receptors
(Padgett and Slesinger, 2010) which are distributed throughout
the CNS and periphery (Ong and Kerr, 1990; Hyland and
Cryan, 2010). GABAB receptors can function to regulate ion
channels (activate K+ and inhibit Ca2+ channels) and cellular
signaling (adenylate cyclase, MAPK; Kornau, 2006; Jiang et al.,
2012), limit the release of neurotransmitters (GABA, glutamate;
Pinard et al., 2010; Gassmann and Bettler, 2012), and dampen
depolarisation induced by excitatory neurotransmitters. GABAB
receptors are implicated in a variety of neurodegenerative,
neuroinﬂammatory, and pathophysiological disorders including
depression, spasticity, pain, and schizophrenia (Reyes-García
et al., 2007; Bjurstöm et al., 2008; Garcia-Oscos et al., 2012).
Given previous reports linking TLR’s and the GABAB receptor
subtype with neuroinﬂammation, particularly with relevance to
MS pathogenesis, we sought to explore the impact of baclofen
(the GABAB receptor agonist) on TLR3 and TLR4-induced
inﬂammatory signaling both centrally and in the periphery, using
murine glial cells and human peripheral blood mononuclear
cells (PBMCs) isolated from healthy individuals and newly-
diagnosed patients with the relapsing-remitting (RR) form of
MS patients. This study identiﬁes baclofen as a diﬀerential
regulator of TLR3 and TLR4 signaling in glia and immune
cells, and oﬀers insight on the role of baclofen in regulating
the innate immune response in cellular pathology associated
with MS.
Materials and Methods
Preparation of Primary Mixed Glial Cultures
and Treatments
Primary mixed glia were prepared from the whole brain of
1-day-old C57/BL6 mice and plated (at 5 × 105 cells/ml) as
previously described (Downer et al., 2010). All experiments
were performed under a license issued by the Health Products
Regulatory Authority (Ireland) and in accordance with the
European Directive 86/609/EEC and the guidelines laid down
by the Animal Experimentation Ethics Committee of University
College Cork. After 14 days in culture, mixed glia were treated
with the TLR4 ligand LPS (100 ng/ml; Sigma–Aldrich, UK),
the TLR3 ligand Poly(I:C) (10 μg/ml; InvivoGen, France) or
vehicle (sterile H2O) for timepoints ranging from 10 min–
24 h. In a second series of experiments, mixed glia were
exposed to the GABAB agonist baclofen (10, 30, and 100 μM;
Sigma–Aldrich, Germany) for 30 min prior to LPS (100 ng/ml;
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30 min and 24 h) or Poly(I:C) (10 μg/ml; 6 h and 24 h)
exposure.
Patients and Blood Samples
Healthy donors and RR-MS patients attending outpatient clinics
at the Mercy University Hospital, Cork, were recruited for
this study. Written informed consent was obtained from each
participant and the study received ethical approval from the
Clinical Research Ethics committee of the Cork Teaching
Hospitals (CREC). Patient recruitment into the study was via
a Senior Consultant Neurologist and patients had to meet
the revised MacDonald diagnostic criteria for clinically deﬁned
MS (Polman et al., 2011) including patient history, clinical
signs and symptoms, physical examination, and adjunctive
diagnostic tools including MRI. The Disability Status Scale
scores were taken using the Expanded Disability Status Scale
(EDSS) by a Senior Consultant Neurologist in an outpatient
clinic. All conﬁrmed MS patients had a RR form of MS as
deﬁned by the revised McDonald criteria. Disease severity
was scored at time of collection using the Kurtzke’s (1983)
EDSS. Patients with RR-MS were clinically stable and naïve to
disease modifying therapies including IFN-β, glatiramer acetate,
ﬁngolimod, teriﬂunomide, dimethyl fumarate, natalizumab, and
alemtuzumab. PBMCs were collected from venous blood of
healthy controls participants (mean age 30.3 ± 1.4 years;
n = 16) and RR-MS patients (mean age 39.3 ± 3.2 years;
n = 8) by way of venipuncture as previously described
(Downer et al., 2013b). Details of the patient demographics are
presented in Figure 3A. Human PBMCs were prepared from
heparinized venous whole blood samples (50 ml per donor) from
individuals by density separation over LymphoprepTM (Axis-
Shield, Norway). PBMCs were plated (1 × 106 cells/ml) on
24-well plates prior to treatment. Plasma samples were separated
following centrifugation, aliquoted, and stored at −80◦C for
subsequent analysis via ELISA.
Cytokine Analysis in Culture Supernatants
Mixed glia (5 × 105 cells/ml) and PBMCs (1 × 106 cells/ml) were
seeded overnight in 24-well plates. Cells were incubated with LPS
(100 ng/ml) or Poly(I:C) (10 μg/ml) for timepoints ranging from
10 min–24 h. Mixed glia/PBMCs were also pre-exposed (30 min)
to baclofen (10, 30, and 100μM) prior to LPS (100 ng/ml; 24 h) or
Poly(I:C) (10 μg/ml; 24 h) exposure. Supernatants were assayed
for tumor necrosis factor-α (TNF-α) and IL-8 concentration by
ELISA according to manufacturer’s instructions (Duoset, R&D
Systems, Abingdon, UK).
Quantitative Real-Time PCR
RNA was extracted from PBMCs (untreated) using a
NucleoSpin
R©
RNAII isolation kit (Macherey-Nagel Inc.,
Geschäftsführer, Germany). The concentration of RNA was
determined using a UV/V is spectrophotometer. cDNA synthesis
was performed on 1 μg RNA using a High Capacity cDNA RT
Kit (Applied Biosystems, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Equal amounts of cDNA were used
for RT-PCR ampliﬁcation. Real-time PCR primers were delivered
as “Taqman
R©
Gene Expression Assays” containing forward and
reverse primers, and a FAM-labeled MGB Taqman probe for
the target gene (Applied Biosystems). GABAB1 primers were
used to assess the expression of the target gene (Taqman Gene
Expression Assay no. Hs00181306_m1). cDNA (1:4 dilution)
was prepared and real-time PCR performed using Applied
Biosystems 7300 Real-time PCR System. cDNA was mixed
with qPCRTM Mastermix Plus (Applied Biosystems) and the
respective gene assay in a 25 μl volume (10 μl of diluted cDNA,
12.5 μl Taqman
R© Universal PCR Mastermix, 1.25 μl target
primer and 1.25 μl 18S). Eukaryotic 18S rRNA was used as
an endogenous control and expression was conducted using a
gene expression assay containing forward and reverse primers
and a VIC-labeled MGB Taqman probe (#4319413E; Applied
Biosystems, USA). Samples were run in duplicate and 40 cycles
were run as follows: 10 min at 95◦C and for each cycle, 15 s
at 95◦C and 1 min at 60◦C. Gene expression was calculated
relative to the endogenous control and analysis was performed
using the 2−CT method. In all experiments no change in
relative 18S rRNA expression between treatment groups was
observed.
TNF-α and IL-8 Measurement in Plasma
Plasma samples from healthy donors and RR-MS patients
were analyzed for concentrations of TNF-α and IL-8 by
ELISA (Duoset, R&D Systems, UK) according to manufacturer’s
instructions.
Immunocytochemistry
Mixed glia (5 × 105 cells/ml) and PBMCs (1 × 106 cells/ml)
were seeded overnight on 13-mm diameter coverslips coated
with poly-l-lysine (Sigma–Aldrich) and grown for 24 h. Cells
were incubated with LPS (100 ng/ml) or Poly(I:C) (10 μg/ml)
for timepoints ranging from 10 min–24 h. Mixed glia/PBMCs
were also pre-exposed (30 min) to baclofen (10, 30 and 100 μM)
prior to LPS (100 ng/ml; 30 min) or Poly(I:C) (10 μg/ml;
6 h) exposure. Cells were then ﬁxed in ice-cold methanol
for 10 min, permeabilized with 0.2% Triton X-100 (Thermo
Fisher Scientiﬁc, Waltham, IL, USA) in PBS for 10 min at
room temperature and blocked with 10% goat serum (Vector
Laboratories, Peterborough, UK) for 2 h. Cells were treated
overnight at 4◦C with rabbit polyclonal NF-κB p65 antibody
(1:200 in 5% goat serum; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Cells were then washed and incubated with
goat anti-rabbit Alexa488 secondary antibody (1:1000 in 5%
goat serum; Invitrogen, Dublin, Ireland) and 4′,6-diamidino-2-
phenylindole (DAPI; 1.5 μg/ml) in PBS, washed, and mounted
(Vectashield; Vector Laboratories). Cells were imaged using an
Olympus IX70 inverted microscope. The ﬂuorescence intensity
in the nucleus of individual cells stained for NF-κB p65 was
measured using the Image J analysis software (Rasband,WJ,
http://rsb.info.nih.gov/ij/). The relative ﬂuorescence intensity
was calculated as the intensity after subtraction of the background
noise. For each treatment, six coverslips were stained and ﬁve
ﬁelds of view were captured per coverslip. Negative control
experiments were performed by replacing the primary antibody
with PBS and using equal gain settings during acquisition and
analysis.
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Statistical Analysis
Data were analyzed using one-way or two-way analysis of
variance (ANOVA) as appropriate. When analysis by ANOVA
indicated signiﬁcance (P < 0.05), the post hoc Student Newman–
Keuls test was used. Correlation tests were performed using two-
tailed Spearman (non-parametric) correlation coeﬃcient. Data
are expressed as means ± SEs of the mean (SEM).
Results
TLR4 Activation Time-Dependently Increases
Nuclear NF-κB p65 Expression and TNF-α
Release in Mixed Glia
TLR4 and TLR3 were initially targeted given their involvement
in EAE progression (Touil et al., 2006) and evidence that their
expression is dysregulated in MS lesions (Bsibsi et al., 2002).
To initially characterize the impact of TLR4 stimulation on pro-
inﬂammatory signaling in primary murine mixed glial cells, we
temporally assessed the impact of LPS on the distribution of
the NF-κB p65 subunit in response to LPS treatment. Firstly,
mixed glia were stimulated with LPS for various timepoints
ranging from 10 min–24 h, and the localization of endogenous
p65 was assessed by immunoﬂuorescence (Figures 1A,B). In
vehicle-treated glial cells, p65 is predominantly cytoplasmic, as
evidenced by the detection of 488-conjugated immunocomplexes
outside of the DAPI-stained regions (Figure 1B). Stimulation
of glia with LPS time-dependently promoted the accumulation
of p65 in the nucleus, peaking at 30 min and 1 h post-
LPS exposure (Figures 1A,B). We next characterized the
impact of TLR4 activation on TNF-α protein production in
primary mixed glia. LPS time-dependently enhanced TNF-α
expression in primary murine mixed glial cells, with mean
maximal stimulatory eﬀects on protein expression observed at
6–24 h (Figure 1C), indicating that TLR4 stimulation promotes
inﬂammatory signaling in primarymouse glial cells in our culture
system.
TLR3 Activation Enhances Nuclear NF-κB p65
Expression and TNF-α Release in Mixed Glia
To assess the impact of TLR3 stimulation on inﬂammatory
signaling events in mixed glial cells, we next assessed the eﬀect of
poly(I:C) exposure on the distribution of the NF-κB p65 subunit.
Primary murine glial cells were incubated with poly(I:C) for
timepoints ranging from 10 min–24 h, and the localization of
the p65 subunit assessed by immunoﬂuorescence (Figures 1D,E).
TLR3 stimulation time-dependently promoted the accumulation
of NF-κB in the nucleus, peaking at 6 and 8 h post-poly(I:C)
exposure (Figures 1D,E). This temporal proﬁle diﬀered in
response to TLR4 stimulation, where maximal sequestration of
NF-κB p65 was observed at 30 min and 1 h post-LPS treatment
(Figure 1A). Poly(I:C) signiﬁcantly enhanced TNF-α expression
in mixed glial cells, with mean maximal stimulatory eﬀects on
protein expression observed at 24 h (Figure 1F). This indicates
that TLR3 and TLR4 activation in primary glia robustly enhances
pro-inﬂammatory signaling in primary murine glial cells.
Effect of the GABAB Receptor Agonist
Baclofen on TLR4-Induced NF-κB-p65 Nuclear
Expression and Pro-Inflammatory Cytokine
Release in Mixed Glia
We next examined the impact of the GABAB agonist baclofen on
TLR4-induced inﬂammatory signaling events in primary mixed
glia. Glial cultures were pre-treated (30 min) with baclofen (10,
30, and 100 μM) prior to LPS exposure (30 min) and nuclear
expression of NF-κB-p65 measured by ﬂuorescence microscopy
(Figures 2A,B). Stimulation of glia with LPS promoted the
accumulation of p65 in the nucleus (Figure 2A). Pre-exposure
to baclofen (at 30 μM) signiﬁcantly attenuated the LPS-induced
accumulation of p65 in the nucleus, while pre-incubation of glia
with the GABAB agonist at concentrations of 10 μM (p = 0.09)
and 100 μM (p = 0.85), failed to signiﬁcantly impact LPS-
induced nuclear p65 sequestration (Figures 2A,B). Similarly,
Figure 2C demonstrates that baclofen attenuated LPS-induced
TNF-α production in glia at concentrations of 10 and 30 μM,
although this did not reach statistical signiﬁcance. These ﬁndings
suggest that the proclivity of baclofen to impact TLR4 signaling
in primary mixed glia is concentration dependent.
GABAB Receptor Activation Modulates
TLR3-Induced NF-κB-p65 Nuclear Expression
and TNF-α Expression in Glia
Given that GABAB activation modulates TLR4-induced signaling
in glia, we next assessed the impact of baclofen on TLR3-induced
inﬂammatory signaling in glial cells. Pre-incubation of glia
with baclofen dose-dependently attenuated poly(I:C)-induced
nuclear sequestration (at 6 h) of NF-κB, reaching signiﬁcance
at 100 μM (Figures 2D,E). Baclofen reduced poly(I:C)-induced
TNF-α production in glia at concentrations of 100 μM, although
this did not reach statistical signiﬁcance (Figure 2F). These
ﬁndings suggest that GABAB activation regulates TLR3 signaling
to NF-κB in glia in a concentration-dependent manner.
Demographic Data of Human Participants
A total of 24 subjects were assessed consisting of healthy control
participants (n = 16) and newly diagnosed RR-MS patients
(n = 8). All RR-MS patients were drug naïve at the time of
inclusion. Mean disease duration in the RR-MS cohort was
1.2 ± 0.3 years and subjects had mild to moderate disability as
reﬂected by EDSS scores of 2.6 ± 0.4 on average. The mean
age of the 24 participants who enrolled in the investigation was
33.1 ± 7.8 years (range 23–40 years in control cohort; range 31–
54 years in RR-MS cohort) and 46% of the sample was female.
The overall demographics of the participants are reported in
Figure 3A.
Cytokine and Chemokine Analysis in Human
Plasma
To determine if RR-MS is associated with alterations in peripheral
inﬂammatory signature, we initially assessed plasma levels of the
inﬂammatory chemokine IL-8 and cytokine TNF-α in plasma
from control and RR-MS groups. No signiﬁcant diﬀerence in
plasma IL-8 (p = 0.94) and TNF-α (p = 0.28) concentration
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FIGURE 1 | TLR4 and TLR3 stimulation promotes NF-κB p65 distribution
to the nucleus and pro-inflammatory TNF-α expression in primary mixed
glial cell cultures. (A,D) The relative fluorescence intensity (corrected total cell
fluorescence; CTCF) of nuclear NF-κB p65 subunit was determined using Image
J to assess the subcellular localization of p65 in mixed glial cultures following
exposure to (A) LPS and (D) poly(I:C) for the indicated time periods. (B,E)
Immunofluorescent images assessing the subcellular localization of p65 in
mixed glial cultures following exposure to (B) LPS and (E) poly(I:C) for the
indicated time periods. Nuclei were stained with DAPI, and images obtained
using an Olympus IX70 inverted microscope equipped with the appropriate filter
sets. Data are presented as the mean ± S.E.M and are representative of six
animals. Scale bar = 20μm. Mixed glial cells were incubated with (C) LPS and
(F) poly(I:C) (timepoints from 10 min–24 h) and supernatants were analyzed for
TNF-α production using ELISA. Data are presented as the mean ± SEM of
triplicate determinations and are representative of six animals. ∗p < 0.05,
∗∗p < 0.01 compared with vehicle-treated cells.
was found between groups (Figure 3B). Detection rates and
mean values of plasma TNF-α and IL-8 are summarized in
Figure 3B. In addition, no clear correlation between the levels of
plasma cytokines and participant age was determined in either
RR-MS patient or control groups (two-tailed Spearman non-
parametric correlation coeﬃcient; Figures 3C,D), indicating that
participant age had no impact on peripheral cytokine/chemokine
expression. We next assessed the impact of gender on plasma
cytokine and chemokine levels. Interestingly, compared to
male control subjects, the expression levels of TNF-α and
IL-8 were signiﬁcantly reduced in female control subjects
(Figure 3E). No signiﬁcant diﬀerence was determined between
males vs. females in the RR-MS cohort (Figure 3F). This
data indicates that the level of cytokine/chemokine expression
in healthy individuals is higher in males than females, but
that this gender diﬀerence is not apparent in the RR-MS
cohort.
GABAB Expression in Human PBMCs
To determine the expression proﬁle of the metabotropic receptor
GABAB in human PBMCs, and whether this proﬁle was altered in
disease, we assessed the expression of GABAB1 subunit in PBMCs
isolated from healthy volunteers and RR-MS patients. Detectable
levels of the GABAB1 subunit was determined in human PBMCs,
with RR-MS associated with a reduction (twofold) in endogenous
GABAB1 expression when compared to PBMCs isolated from
healthy subjects (Figure 3G). This indicates that downregulation
of GABAB receptors occurs in PBMCs isolated from newly
diagnosed RR-MS patients, when compared to immune cells from
healthy subjects.
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FIGURE 2 | GABAB receptor activation modulates TLR4- and
TLR3-induced NF-κB-p65 nuclear expression and TNF-α expression
release in glia. (A,D) CTCF of nuclear NF-κB p65 subunit in mixed glial
cultures following exposure to (A) LPS (30 min) and (D) poly(I:C) (6 h) in the
absence and presence of baclofen (10, 30, and 100 μM). (B,E)
Immunofluorescent images demonstrating the subcellular localization of p65 in
glia following exposure to (B) LPS ± baclofen and (E) poly(I:C) ± baclofen.
Nuclei were stained with DAPI, and images obtained using an Olympus IX70
inverted microscope equipped with the appropriate filter sets. Data are
presented as the mean ± SEM and are representative of six animals. Scale
bar = 20 μm. Mixed glial cells were pre-incubated with baclofen (10, 30, and
100 μM) prior to (C) LPS and (F) poly(I:C) (both at 24 h) and supernatants
analyzed for TNF-α expression by ELISA. Data are presented as the
mean ± SEM of triplicate determinations from six animals. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 compared with vehicle-treated cells. #p < 0.05
compared to cells treated with LPS or Poly(I:C) in the absence of baclofen.
Effect of TLR3 and TLR4 Stimulation on
PBMCs Isolated from Control and RR-MS
Cohorts
Given the deﬁned role of TLR3 and TLR4 in EAE progression
(Touil et al., 2006), in addition to evidence that their expression
is up-regulated in MS lesions (Bsibsi et al., 2002), we next set
out to assess the impact of TLR3 and TLR4 stimulation on
inﬂammatory responses of immune cells isolated from control
and RR-MS patients. Firstly, supernatants from unstimulated
PBMCs isolated from RR-MS patients displayed enhanced TNF-
α (Figures 4A,C) and IL-8 (Figures 4B,D) expression, when
compared to PBMCs from healthy subjects, indicating the RR-MS
patient PBMCs display an enhanced endogenous inﬂammatory
signature. LPS enhanced TNF-α production in PBMCs from both
groups (Figure 4A), and importantly the production of TNF-α
was exacerbated in PBMCs prepared from the RR-MS group,
compared with the control cohort (Figure 4A). In terms of IL-
8 expression, two-way ANOVA revealed a signiﬁcant inﬂuence
of disease status on IL-8 levels [F(1,30) = 4.773, p = 0.0369], but
no signiﬁcant inﬂuence of TLR4 stimulation on overall variation
[F(2,30) = 0.7174, p = 0.4962] (Figure 4B). However, post hoc
analysis revealed a trend toward a statistically signiﬁcant increase
in IL-8 release following LPS treatment in PBMCs isolated
from healthy controls (p = 0.0612), but not in RR-MS patients.
Interestingly, PBMCs isolated from healthy subjects and RR-
MS patients were unresponsive to poly(I·C) stimulation, both in
terms of TNF-α and IL-8 production (Figures 4C,D), indicating
that PBMCs from control individuals and RR-MS patients
are refractory to TLR3 stimulation, in terms of TNF-α and
IL-8 signaling.
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FIGURE 3 | Demographic and clinical characteristics of MS patients
and control subjects included in the study. (A) Demographics of
healthy control participants and RR-MS patients. Expanded Disability
Status Scale (EDSS). (B) Plasma levels of IL-8 and TNF-α in control
(n = 16) and MS (n = 8) cohort. Detection rates and mean plasma
expression values of IL-8 and TNF-α are summarized. (C,D) Correlation
between IL-8/TNF-α plasma levels and age of study participants.
Correlation plots demonstrating (C) IL-8 and (D) TNF-α plotted against
subject age. No correlation was observed between age in control and
MS groups analyzed (two-tailed Spearman non-parametric correlation
coefficient, correlation r-values, and significance p-values, are indicated in
the graphs). Levels of TNF-α and IL-8 in (E) healthy control participants
and (F) MS patients in plasma obtained from male (n = 13) and female
(n = 11) participants. (G) Peripheral blood mononuclear cells (PBMCs)
isolated from healthy subjects and newly diagnosed RR-MS patients were
assessed for GABAB mRNA expression, cDNA generated and assayed by
quantitative real-time PCR for levels of GABAB1 mRNA. Data are
presented as the mean ± SEM of triplicate determinations. ∗p < 0.05
compared with male control subjects (E). ∗p < 0.05 compared with all
control subjects (G).
Baclofen Attenuates TLR4-Induced TNF-α
Cytokine Release in Human PBMCs Isolated
from Healthy, but not RR-MS, Subjects
Given that GABAB activation modulates TLR4-induced signaling
in primary mixed glia (Figure 2), and that TLR4 stimulation
enhances TNF-α signaling in PBMCs from control and RR-MS
patients (Figure 4), we next assessed the proclivity of baclofen
to modulate TLR4-induced TNF-α release in PBMCs isolated
from healthy subjects and RR-MS patients. PBMCs from healthy
subjects (Figure 5A) and RR-MS patients (Figure 5B) were pre-
treated (30 min) with baclofen (10, 30, and 100 μM) prior to
LPS exposure (24 h) and TNF-α expression assessed. PBMCs
isolated from healthy subjects were responsive to LPS with an
increase in TNF-α release observed, whereas baclofen modestly
attenuated this (Figure 5A). In contrast, pre-exposure (30 min)
to baclofen prior to LPS exposure (24 h) failed to signiﬁcantly
impact TLR4-induced TNF-α expression in PBMCs from RR-
MS patients at each dose tested (Figure 5B). Importantly, this
indicates a diﬀerential sensitivity of cells from healthy and RR-MS
subjects in terms of the ability of baclofen to modulate TLR-
induced inﬂammatory signaling, which may have implications
in terms of the design of GABAB receptor therapeutics to treat
neuroinﬂammatory disorders including MS.
Discussion
Understanding the mechanisms underlying neuroinﬂammatory
processes in MS may pave the way to novel therapeutic
strategies. Data herein demonstrate that the GABAB receptor
agonist baclofen has the proclivity to diﬀerentially target
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FIGURE 4 | Peripheral blood mononuclear cells from RR-MS patients
display enhanced inflammatory signaling. PBMCs prepared from healthy
subjects and MS patients were seeded into 24-well plates and treated with
vehicle, LPS (100 ng/ml) or poly(I·C) (10 μg/ml) for 24 h. Supernatants were
analyzed for TNF-α (A,C) and IL-8 (B,D) production using ELISA. Data are
presented as the mean ± SEM of triplicate determinations. ∗p < 0.05 and
∗∗p < 0.01 compared with vehicle-treated PBMCs from healthy subjects.
###p < 0.001 compared with vehicle-treated cells from MS patients.
TLR4 and TLR3 inﬂammatory signaling events both in
CNS glial cells, and in peripheral immune cells. Baclofen
reduced TLR3/4-induced nuclear NF-κB and TNF-α (albeit
modestly) expression in glial cells, with distinct dose-
dependency identiﬁed for these eﬀects. GABAB receptor
activation attenuated TLR4-induced TNF-α expression in
PBMCs isolated from healthy individuals, while baclofen
had no impact on TLR4 signaling in RR-MS patient PBMCs.
Furthermore, PBMCs from RR-MS patients expressed lower
levels of the GABAB receptor mRNA. Signiﬁcantly, we also
determined that immune cells from the RR-MS patient group
displayed hypersensitivity to LPS exposure in terms of TNF-α
expression.
TLR family members are expressed in cells of the CNS
(Downer et al., 2013a; Nakano et al., 2015) and TLR ligands
regulate CNS inﬂammation (Lehnardt, 2010). We initially
targeted TLR3 and TLR4 signaling given the role of these
receptors in neuroinﬂammatory events linked with MS (Bsibsi
et al., 2002; Touil et al., 2006). Both NF-κB activation and
pro-inﬂammatory cytokine expression are known downstream
signaling events following ligation of TLR3 and TLR4 (Moynagh,
2005), and signaling via both cascades is perturbed following
TLR3 (Cavassani et al., 2008) and TLR4 (Devaraj et al., 2011)
knockout. We examined the ability of LPS and poly(I:C) to
couple to TLR4 and TLR3 inﬂammatory signaling in primary
glia, respectively. Data presented herein indicate that LPS
and poly(I:C) enhanced NF-κB activation and TNF-α cytokine
expression in glia, with the kinetics of this response mirroring
data described elsewhere (Park et al., 2006; Horvath et al., 2008).
This study highlights the anti-inﬂammatory potential of
baclofen in glial cells, by virtue of its inhibitory eﬀects on the
NF-κB-TNF-α pathway induced by TLR3/4 activation. This is
consistent with data elsewhere indicating that baclofen reduces
LPS-induced production of IL-6/IL-12 inmouse microglia (Kuhn
et al., 2004), and reduces phospho-p65-NF-κB and IL-6/TNF-α
expression in human astrocytes and microglial cells stimulated
with IFN-γ/LPS (Lee et al., 2011). GABAB receptors are expressed
on astrocytes and microglia (Charles et al., 2003), and evidence
indicates that glial GABAB receptors are functional (Kuhn et al.,
2004; Oka et al., 2006). Given the expression and functional
activity of GABAB receptors on glia, alongside evidence that
baclofen negatively regulates TLR3/4-induced inﬂammatory
signaling, it is likely that GABAB receptors play an integral role in
the course of neuroinﬂammation by targeting glia. The ability of
baclofen to target TLR3/4-induced inﬂammatory signaling in glia
in vitro may contribute to an anti-inﬂammatory eﬃcacy in vivo,
and this will be the focus of further studies.
Interestingly, diﬀerent eﬀects of GABAB receptor modulation
on the immune system have been indicated, suggesting that
GABA is a regulator of immune cell activity and inﬂammation.
Indeed, GABA receptors have been identiﬁed on neutrophils,
macrophages, dendritic cells, and T-cells (Rane et al., 2005; Jin
et al., 2013), and cells of the immune system possess the metabolic
machinery for the synthesis of GABA (Auteri et al., 2015). Given
the evidence that GABA is a neuroimmune modulator, alongside
our ﬁndings that baclofen modulates TLR-induced inﬂammatory
signaling in central glial cells, we next assessed the impact of
baclofen on TLR signaling in peripheral immune cells. Firstly,
our ﬁndings indicate that TLR4 activation promotes TNF-α and
IL-8 cytokine expression in human PBMCs, and these ﬁndings
are consistent with data elsewhere (Kaplin et al., 2009; Downer
et al., 2013b). Importantly, data presented herein indicate an
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FIGURE 5 | GABAB activation attenuates TLR4-induced TNF-α
production in PBMCs from healthy, but not MS, subjects. PBMCs
isolated from (A) healthy subjects and (B) MS patients were seeded in 24-well
plates and pre-treated with baclofen (10, 30, and 100 μM) in the absence and
presence of LPS (100 ng/ml) for 24 h. Supernatants were analyzed for TNF-α
production using ELISA. Data are presented as the mean ± SEM of triplicate
determinations. ∗∗p < 0.01 and ∗∗∗p < 0.001 compared with vehicle-treated
cells. ##p < 0.01 and ###p < 0.001 compared to cells treated with LPS in the
absence of baclofen.
anti-inﬂammatory propensity of baclofen in human immune
cells, demonstrating that baclofen blunts LPS-induced TNF-α
expression in peripheral immune cells from healthy subjects.
This ﬁnding is in line with data demonstrating that exposure
of human PBMCs to baclofen ameliorates phytohemagglutinin-
induced TNF-α release (Duthey et al., 2010). A signiﬁcant ﬁnding
here is that this is the ﬁrst direct evidence that baclofen can target
TLR signaling in human PBMCs, and hence has relevance across
a range of neuroimmune disorders.
Our results identify that PBMCs isolated from healthy subjects
were responsive to baclofen, with a signiﬁcant, albeit moderate,
decrease in LPS-induced TNF-α expression observed following
baclofen treatment. In contrast, baclofen failed to regulate TLR4-
induced TNF-α expression in PBMCs from RR-MS subjects. This
is signiﬁcant as intrathecal administration of baclofen can be used
to treat spasticity inMS, in addition to spinal cord injury, cerebral
palsy, and acquired brain injury (Gunnarsson and Samuelsson,
2015). Furthermore, there is evidence of a loss of GABAergic
neurons at lesion sites in post-mortem MS brain (Redondo et al.,
2014). The diﬀerential sensitivity of cells from healthy and RR-
MS subjects to baclofen indicates that MS drives a desensitizing
signal in terms of GABAB receptor function. Indeed, our ﬁndings
indicate that downregulation of GABAB receptors occurs in
PBMCs in newly diagnosed RR-MS patients, which may govern
the diﬀerential sensitivity to baclofen exposure seen in healthy
and MS patient cells. In support of this, the level of GABA is
reduced in the blood serum of patients with MS as compared
to the controls (Demakova et al., 2003). In addition, baclofen
treatment has been shown to reduce GABAB receptor density
in rat spinal cord (Kroin et al., 1993), which may be postulated
as a molecular mechanism for development of tolerance. It is
especially interesting to note that treatment failure has been
shown with baclofen in MS patients (Stroet et al., 2013), and the
inability of baclofen to target TLR4-induced pro-inﬂammatory
cytokine production might contribute to these eﬀects.
Whether the eﬀects of baclofen identiﬁed in the present
and other studies are a direct result of its action at the
GABAB receptor is not yet entirely clear, particularly given the
recent discovery that baclofen, and several GABAB receptor
antagonists, are allosteric modulators of CXCR4, a chemokine
receptor involved in neuroimmune crosstalk (Guyon et al.,
2013). Indeed, determining whether the eﬀects of baclofen
that were observed in this study are speciﬁcally due to its
action at the GABAB receptor rather than at CXCR4 will be
the focus of future studies. Such studies will be challenging
because several GABAB receptor antagonists also act as allosteric
modulators of CXCR4 (Guyon et al., 2013). Future studies aimed
at identifying GABAB receptor antagonists that do not aﬀect
CXCR4 activity will be required in order to address this question
directly. Nevertheless, since baclofen and some GABAB receptor
antagonists exert the same eﬀects on CXCR4 activity (Guyon
et al., 2013), then it would be expected that prevention of the
eﬀects of baclofen by a GABAB receptor antagonist would be
independent of CXCR4 activity (since both baclofen and the
GABAB receptor antagonists behave as CXCR4 antagonists).
Alternatively, experiments could examine the eﬀects of baclofen
under conditions whereby CXCR4 expression or activity is
altered, however, such experiments might be complicated by the
modulation of inﬂammatory mediators by CXCR4 itself. Despite
these limitations, there is accumulating evidence that many
components of the GABA neurotransmitter system, including
not only the GABAB receptor but also the GABAA receptor, can
have anti-inﬂammatory eﬀects (Song et al., 1998; Bhat et al., 2010;
Lee et al., 2011).
The rationale behind the present study was to determine
if baclofen could target TLR-induced signaling in RR-MS,
particularly given the growing body of data indicating that
the TLR system is a key player in MS pathogenesis (O’Brien
et al., 2008; Downer, 2011). However, intrathecal administration
of baclofen is used to manage spasticity in patients with a
range of conditions including spinal cord injury, cerebral palsy
and acquired brain injury in addition to MS, and hence in
future studies it would be interesting to compare the eﬀects
of baclofen on the PBMCs of patients with other neurological
conditions.
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The concentrations of cytokines/chemokines are altered in
MS (Ubogu et al., 2006), suggesting that cytokine/chemokine
signatures may indicate disease progression in patient groups
(O’Connell et al., 2014). Given that evidence indicates that
TNF-α (Sharief and Hentges, 1991) and IL-8 (Lund et al.,
2004) are higher in serum of patients with MS, we examined
the relative expression of TNF-α and IL-8 in plasma isolated
from newly diagnosed RR-MS patients. Our analysis revealed
no diﬀerence in plasma IL-8/TNF-α between control and
RR-MS groups. Systemic inﬂammation in MS is strongly
associated with periods of intense relapse (Confavreux et al.,
2000), hence it is plausible that alterations in peripheral
cytokines in MS may be phase dependent. In support of this,
Mellergard et al. (2010) indicate that MS patients with EDSS
measurements in the range comparable to the RR-MS cohort
assessed in present study demonstrate no alteration in plasma
TNF-α when compared to healthy subjects (Mellergard et al.,
2010).
Neuroinﬂammatory changes develop with age, with defects
in the immune system identiﬁed in elderly individuals (Allman
and Miller, 2005). In addition, an increased plasma level of
pro-inﬂammatory cytokines has been demonstrated in elderly,
compared to young, individuals (Forsey et al., 2003). Our
ﬁndings indicate no clear correlation between the levels of plasma
cytokine/chemokine and participant age in either RR-MS or
control groups, indicating that the age of subjects did not impact
cytokine/chemokine proﬁles. Interestingly, compared to male
control subjects, the expression levels of TNF-α and IL-8 were
signiﬁcantly reduced in female control subjects. This indicates
that particular expression proﬁles of cytokines/chemokines may
be gender speciﬁc, which is conﬁrmed elsewhere (Asai et al.,
2001).
Marked alterations in the expression proﬁle of TLRs has
been determined in MS lesions in human brain samples, in
the brain samples from mice that have undergone EAE, and
in CSF cells isolated from MS patients (Marta, 2009). With
this in mind we investigated the eﬀect of TLR4 and TLR3
stimulation on the pro-inﬂammatory cytokine and chemokine,
TNF-α and IL-8. PBMCs without stimulation, as well as after
stimulation with LPS, displayed increased production of TNF-α
and IL-8 in the RR-MS sample cohort, when compared to
the control group. These results suggest that immune cells
from the RR-MS patient group have an enhanced endogenous
inﬂammatory signature. In addition, RR-MS patient PBMCs
displayed hypersensitivity to LPS exposure in terms of TNF-α
expression. TLR4 expression is upregulated in CNS lesions
in mice following EAE and in PBMCs from RR-MS and
secondary progressive (SP) MS patients (Andersson et al., 2008),
which in support of our study, indicates that TLR4 signaling
participates in an innate immune response that may shape the
inﬂammatory response in both forms of MS. It is intriguing
that the hypersensitivity of RR-MS patient cells to LPS is only
relevant in the context of TNF-α induction, since LPS shows
comparable eﬃcacy in inducing IL-8 in cells from healthy and
RR-MS patients. Hence, any form of TLR4 hypersensitivity
that may exist in MS patient cells appears to be restricted
to the pathway leading to TNF-α expression, and further
studies will probe the intracellular signaling events in patient
cells.
Our studies also probed the eﬀects of TLR3 stimulation
on TNF-α/IL-8 in PBMCs. Surprisingly, PBMCs isolated from
healthy donors and RR-MS patients did not respond to TLR3
stimulation by enhancing TNF-α or IL-8 expression, suggesting
that the TLR3 pathway leading to cytokine and chemokine
expression may be desensitized in our participant cohorts.
Indeed, we have previously demonstrated that the TLR3-IFN-β
pathway is desensitized in MS patient PBMCs, suggesting that
MS patients may be pre-sensitized to viral infection showing
some form of TLR3 tolerance. However, the non-responsiveness
of healthy donor PBMCs to poly(I·C) is in line (Wesch et al.,
2006) and in contrast (Myles et al., 2012) to ﬁndings elsewhere
in studies which investigated freshly isolated PBMCs; diﬀerences
in dose and timecourse for treatment regimen used with poly(I:C)
in the present study may underlie the diﬀerences observed.
Although baclofen demonstrates therapeutic eﬀects in MS,
the mechanism(s) of action are poorly understood. We present
evidence that the innate arm of the immune system is a target
for baclofen anti-inﬂammatory action, and demonstrate that
baclofen diﬀerentially targets TLR4 and TLR3 inﬂammatory
signaling events both in primary murine glial cells and in
PBMCs isolated from human blood samples. Baclofen can
exert anti-inﬂammatory properties at speciﬁc doses, by down-
regulating TLR-induced activation of NF-κB and induction
of pro-inﬂammatory cytokines. Signiﬁcantly, our ﬁndings also
indicate that inﬂammatory signaling, and sensitivity to TLR4
stimulation, was enhanced in PBMCs of patients with RR-MS,
highlighting that TLR4 may play a role at least in the RR
form of MS pathogenesis. We targeted this particular patient
cohort because they were newly-diagnosed and naïve to disease
modifying therapies. However, investigating TLR functioning
and its modulation by baclofen in patients with secondary
chronic progressive MS would be an important future study.
Overall, the present study provides novel insight into the cellular
eﬀects of targeting central and peripheral GABAB receptors in the
modulation of TLR functioning.
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